JPWO2020056160A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020056160A5 JPWO2020056160A5 JP2021514401A JP2021514401A JPWO2020056160A5 JP WO2020056160 A5 JPWO2020056160 A5 JP WO2020056160A5 JP 2021514401 A JP2021514401 A JP 2021514401A JP 2021514401 A JP2021514401 A JP 2021514401A JP WO2020056160 A5 JPWO2020056160 A5 JP WO2020056160A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- inhibitor
- pai
- day
- site
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 161
- 239000003112 inhibitor Substances 0.000 claims description 83
- 230000002401 inhibitory effect Effects 0.000 claims description 83
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims description 82
- 210000004209 Hair Anatomy 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 230000003204 osmotic Effects 0.000 claims description 15
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 14
- -1 2-{[3-(furan-3-yl)phenyl]amino}-2-oxoethoxy Chemical group 0.000 claims description 13
- 239000000839 emulsion Substances 0.000 claims description 13
- 239000006260 foam Substances 0.000 claims description 13
- 239000000725 suspension Substances 0.000 claims description 13
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-Aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 10
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 10
- 229960004050 aminobenzoic acid Drugs 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 239000007908 nanoemulsion Substances 0.000 claims description 7
- 210000003780 Hair Follicle Anatomy 0.000 claims description 6
- 210000003491 Skin Anatomy 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- MSFCICRWSXXZFO-UHFFFAOYSA-N 5-chloro-2-[[2-[3-(furan-3-yl)anilino]-2-oxoacetyl]amino]benzoic acid Chemical compound OC(=O)C1=CC(Cl)=CC=C1NC(=O)C(=O)NC1=CC=CC(C2=COC=C2)=C1 MSFCICRWSXXZFO-UHFFFAOYSA-N 0.000 claims description 5
- 239000005541 ACE inhibitor Substances 0.000 claims description 5
- FAKRSMQSSFJEIM-RQJHMYQMSA-N Captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 5
- 229960000873 Enalapril Drugs 0.000 claims description 5
- GBXSMTUPTTWBMN-XIRDDKMYSA-N Enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 5
- 108010061435 Enalapril Proteins 0.000 claims description 5
- KLZWOWYOHUKJIG-BPUTZDHNSA-N Imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 claims description 5
- 108020004459 Small Interfering RNA Proteins 0.000 claims description 5
- LXMSZDCAJNLERA-ZHYRCANASA-N Spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims description 5
- 102000004965 antibodies Human genes 0.000 claims description 5
- 108090001123 antibodies Proteins 0.000 claims description 5
- 150000001562 benzopyrans Chemical class 0.000 claims description 5
- KAKZBPTYRLMSJV-UHFFFAOYSA-N butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 claims description 5
- 229960000830 captopril Drugs 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- 235000014633 carbohydrates Nutrition 0.000 claims description 5
- 229960004120 defibrotide Drugs 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 5
- 229960001195 imidapril Drugs 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 150000002739 metals Chemical class 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 239000002924 silencing RNA Substances 0.000 claims description 5
- 150000003384 small molecules Chemical class 0.000 claims description 5
- 229960002256 spironolactone Drugs 0.000 claims description 5
- 230000001225 therapeutic Effects 0.000 claims description 5
- 230000000699 topical Effects 0.000 claims description 5
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 4
- SNIOPGDIGTZGOP-UHFFFAOYSA-N 1,2,3-propanetrioltrinitrate Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 4
- RHWRWEUCEXUUAV-ZSESPEEFSA-N 2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid;2-(2-hydroxyethylamino)ethanol Chemical compound OCCNCCO.C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 RHWRWEUCEXUUAV-ZSESPEEFSA-N 0.000 claims description 4
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims description 4
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims description 4
- 229960002117 Triamcinolone Acetonide Drugs 0.000 claims description 4
- YNDXUCZADRHECN-JNQJZLCISA-N Triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 4
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims description 4
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims description 4
- 229960003711 glyceryl trinitrate Drugs 0.000 claims description 4
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 claims description 4
- 229960002240 iloprost Drugs 0.000 claims description 4
- 231100000344 non-irritating Toxicity 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 229940100198 ALKYLATING AGENTS Drugs 0.000 claims description 2
- 229940035676 ANALGESICS Drugs 0.000 claims description 2
- 229940035674 ANESTHETICS Drugs 0.000 claims description 2
- 229940069428 ANTACIDS Drugs 0.000 claims description 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims description 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims description 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims description 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims description 2
- 229940030609 CALCIUM CHANNEL BLOCKERS Drugs 0.000 claims description 2
- RRGUKTPIGVIEKM-UHFFFAOYSA-N Cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 claims description 2
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 claims description 2
- 229960001334 Corticosteroids Drugs 0.000 claims description 2
- NGOGFTYYXHNFQH-UHFFFAOYSA-N Fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 claims description 2
- 229940068052 Ginkgo biloba extract Drugs 0.000 claims description 2
- 239000009429 Ginkgo biloba extract Substances 0.000 claims description 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims description 2
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 2
- 240000008526 Hypericum perforatum Species 0.000 claims description 2
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 claims description 2
- 229960003685 Imatinib mesylate Drugs 0.000 claims description 2
- 208000002260 Keloid Diseases 0.000 claims description 2
- 210000001117 Keloid Anatomy 0.000 claims description 2
- 206010023330 Keloid scar Diseases 0.000 claims description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine zwitterion Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- 229960003987 Melatonin Drugs 0.000 claims description 2
- 239000000006 Nitroglycerin Substances 0.000 claims description 2
- 229940014995 Nitroglycerin Drugs 0.000 claims description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N Pilopine HS Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 claims description 2
- 229940077718 Proton pump inhibitors for peptic ulcer and GORD Drugs 0.000 claims description 2
- 206010037912 Raynaud's phenomenon Diseases 0.000 claims description 2
- 102000003743 Relaxin Human genes 0.000 claims description 2
- 108090000103 Relaxin Proteins 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 229940053479 Selective serotonin reuptake inhibitors Drugs 0.000 claims description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims description 2
- 229960000553 Somatostatin Drugs 0.000 claims description 2
- 102000005157 Somatostatin Human genes 0.000 claims description 2
- 108010056088 Somatostatin Proteins 0.000 claims description 2
- 235000002197 St. John’s wort Nutrition 0.000 claims description 2
- IEHKWSGCTWLXFU-IIBYNOLFSA-N Tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims description 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims description 2
- 229960005032 Treprostinil Drugs 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 239000002160 alpha blocker Substances 0.000 claims description 2
- 230000003444 anaesthetic Effects 0.000 claims description 2
- 230000000202 analgesic Effects 0.000 claims description 2
- 239000003159 antacid agent Substances 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000001458 anti-acid Effects 0.000 claims description 2
- 230000003510 anti-fibrotic Effects 0.000 claims description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 2
- 229960005370 atorvastatin Drugs 0.000 claims description 2
- 230000003115 biocidal Effects 0.000 claims description 2
- 239000000480 calcium channel blocker Substances 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- 229960004588 cilostazol Drugs 0.000 claims description 2
- 229930016911 cinnamic acid Natural products 0.000 claims description 2
- 235000013985 cinnamic acid Nutrition 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 238000002681 cryosurgery Methods 0.000 claims description 2
- 238000000315 cryotherapy Methods 0.000 claims description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000002308 endothelin receptor antagonist Substances 0.000 claims description 2
- 229960002435 fasudil Drugs 0.000 claims description 2
- 239000003193 general anesthetic agent Substances 0.000 claims description 2
- 235000020686 ginkgo biloba extract Nutrition 0.000 claims description 2
- 238000002639 hyperbaric oxygen therapy Methods 0.000 claims description 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims description 2
- 230000001861 immunosuppresant Effects 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 229940079866 intestinal antibiotics Drugs 0.000 claims description 2
- 238000002647 laser therapy Methods 0.000 claims description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 230000035515 penetration Effects 0.000 claims description 2
- 229960001416 pilocarpine Drugs 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 150000003180 prostaglandins Chemical class 0.000 claims description 2
- 239000000612 proton pump inhibitor Substances 0.000 claims description 2
- 230000003482 proton pump inhibitor Effects 0.000 claims description 2
- 239000000018 receptor agonist Substances 0.000 claims description 2
- 238000002271 resection Methods 0.000 claims description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims description 2
- 229960003310 sildenafil Drugs 0.000 claims description 2
- 239000002047 solid lipid nanoparticle Substances 0.000 claims description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 2
- 229960000835 tadalafil Drugs 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 239000003860 topical agent Substances 0.000 claims description 2
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 claims description 2
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 claims description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 2
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 claims description 2
- 102100007015 SERPINE1 Human genes 0.000 claims 25
- 229920002312 polyamide-imide Polymers 0.000 claims 3
- 238000000034 method Methods 0.000 claims 1
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 description 60
- 239000002674 ointment Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731074P | 2018-09-13 | 2018-09-13 | |
| US62/731,074 | 2018-09-13 | ||
| PCT/US2019/050849 WO2020056160A1 (en) | 2018-09-13 | 2019-09-12 | Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021535925A JP2021535925A (ja) | 2021-12-23 |
| JPWO2020056160A5 true JPWO2020056160A5 (hr) | 2022-09-21 |
Family
ID=68052024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514401A Pending JP2021535925A (ja) | 2018-09-13 | 2019-09-12 | プラスミノーゲンアクチベーターインヒビター１（ｐｌａｓｍｉｎｏｇｅｎ ａｃｔｉｖａｔｏｒ ｉｎｈｉｂｉｔｏｒ １）（ＰＡＩ−１）阻害剤（ｉｎｈｉｂｉｔｏｒ）およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220105068A1 (hr) |
| EP (1) | EP3849539A1 (hr) |
| JP (1) | JP2021535925A (hr) |
| KR (1) | KR20210057141A (hr) |
| CN (1) | CN113056268A (hr) |
| AU (1) | AU2019338459A1 (hr) |
| BR (1) | BR112021004542A2 (hr) |
| CA (1) | CA3112558A1 (hr) |
| IL (1) | IL281450A (hr) |
| MX (1) | MX2021002995A (hr) |
| SG (1) | SG11202102478SA (hr) |
| WO (1) | WO2020056160A1 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102487144B1 (ko) | 2016-11-21 | 2023-01-12 | 에이리온 테라퓨틱스, 인코포레이티드 | 큰 물질의 경피 전달 |
| CN113155987B (zh) * | 2020-12-28 | 2023-06-06 | 浙江工商大学 | 一种微针贴片及其制备方法、应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US296006A (en) | 1884-04-01 | John hoefleb | ||
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| US4886499A (en) | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| US6010715A (en) | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1261849B (it) | 1993-09-02 | 1996-06-03 | Avantgarde Spa | Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici. |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| US5965154A (en) | 1998-03-17 | 1999-10-12 | Plc Holding, L.L.C. | Adhesive matrix type transdermal patch and method of manufacturing same |
| US6503231B1 (en) | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
| US6611707B1 (en) | 1999-06-04 | 2003-08-26 | Georgia Tech Research Corporation | Microneedle drug delivery device |
| WO2001051085A1 (en) * | 2000-01-14 | 2001-07-19 | Tanox, Inc. | Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease |
| US6908453B2 (en) | 2002-01-15 | 2005-06-21 | 3M Innovative Properties Company | Microneedle devices and methods of manufacture |
| CA2476761A1 (en) * | 2002-02-19 | 2003-08-28 | Vanderbilt University | Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors |
| US20040043026A1 (en) * | 2002-05-13 | 2004-03-04 | Tai-Lan Tuan | Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions |
| DK3144013T3 (en) | 2005-12-01 | 2019-03-04 | Univ Massachusetts Lowell | Botulinum nanoemulsions |
| EP2015773A4 (en) | 2006-04-27 | 2010-05-05 | Anterios Inc | EXAMINATION OF THE EFFECTS OF TOPICAL ADMINISTRATION OF CHEMICALLY DENOMINATING PHARMACEUTICALS |
| US20100150994A1 (en) | 2006-12-01 | 2010-06-17 | Anterios, Inc. | Amphiphilic entity nanoparticles |
| US20110212157A1 (en) | 2008-06-26 | 2011-09-01 | Anterios, Inc. | Dermal delivery |
| US20120114745A1 (en) * | 2009-06-26 | 2012-05-10 | Nam-Mew Pui | Method for treating or ameliorating mucocutaneous or ocular toxicities |
| EP2667859A2 (en) | 2011-01-24 | 2013-12-04 | Anterios, Inc. | Nanoparticle compositions, formulations thereof, and uses therefor |
| DK2667854T3 (en) | 2011-01-24 | 2019-04-23 | Anterios Inc | NANO PARTICLE FORMATIONS |
| EP2793869B1 (en) | 2011-12-21 | 2015-09-23 | 3M Innovative Properties Company | Transdermal adhesive patch assembly with removable microneedle array and method of using same |
-
2019
- 2019-09-12 CA CA3112558A patent/CA3112558A1/en active Pending
- 2019-09-12 SG SG11202102478SA patent/SG11202102478SA/en unknown
- 2019-09-12 KR KR1020217010851A patent/KR20210057141A/ko unknown
- 2019-09-12 US US17/274,948 patent/US20220105068A1/en active Pending
- 2019-09-12 JP JP2021514401A patent/JP2021535925A/ja active Pending
- 2019-09-12 EP EP19773718.2A patent/EP3849539A1/en active Pending
- 2019-09-12 AU AU2019338459A patent/AU2019338459A1/en active Pending
- 2019-09-12 CN CN201980074633.8A patent/CN113056268A/zh active Pending
- 2019-09-12 BR BR112021004542-2A patent/BR112021004542A2/pt unknown
- 2019-09-12 WO PCT/US2019/050849 patent/WO2020056160A1/en unknown
- 2019-09-12 MX MX2021002995A patent/MX2021002995A/es unknown
-
2021
- 2021-03-11 IL IL281450A patent/IL281450A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20180114911A (ko) | 침습 및 비침습 시술적 피부 관리를 위한 조성물 및 방법 | |
| KR20140003573A (ko) | 오일 조성물 | |
| KR20140004186A (ko) | 표면활성제 조성물 | |
| JP2003521482A (ja) | 治療用組成物およびその使用方法 | |
| US11865217B2 (en) | Transdermal drug delivery system | |
| EP2431031B1 (en) | Composition for preventing hair loss or for stimulating hair growth | |
| WO2012099968A1 (en) | Compositions and methods for treating skin cancer associated diseases | |
| KR20140012651A (ko) | 파라벤 조성물 | |
| KR101267771B1 (ko) | 약제 조합을 이용한 치료 방법 및 이에 적합한 약제 조합 | |
| KR20130065561A (ko) | 점막피부 혹은 안구 독성의 치료 혹은 개선용의 약제학적 조성물 | |
| JP2021535925A (ja) | プラスミノーゲンアクチベーターインヒビター１（ｐｌａｓｍｉｎｏｇｅｎ ａｃｔｉｖａｔｏｒ ｉｎｈｉｂｉｔｏｒ １）（ＰＡＩ−１）阻害剤（ｉｎｈｉｂｉｔｏｒ）およびその使用 | |
| JP2022500452A (ja) | プラスミノーゲンアクチベーターインヒビター１（ｐｌａｓｍｉｎｏｇｅｎ ａｃｔｉｖａｔｏｒ ｉｎｈｉｂｉｔｏｒ １）（ＰＡＩ−１）阻害剤（ｉｎｈｉｂｉｔｏｒ）の使用 | |
| KR20190038840A (ko) | 피부 및/또는 모발 복구를 위한 5-하이드록시트립타민 1b 수용체-자극제 | |
| JPWO2020056160A5 (hr) | ||
| US8404745B2 (en) | Transdermal delivery of medicinal cetylated fatty esters using phonophoresis or iontophoresis | |
| CN114929208A (zh) | 通过调节上皮连接的透皮穿透 | |
| KR20160145818A (ko) | 아르테미시닌 및 그 유도체를 이용한 지루성 각화증의 치료 또는 예방 방법 | |
| KR102465464B1 (ko) | 비타젠을 포함하는 헤어케어용 조성물 | |
| EP3856140A1 (en) | Transdermal drug delivery system | |
| Nassar et al. | Tranexamic acid, a Promising Melasma Treatment Modality; Past and Future Treatment Regimen | |
| JPWO2020056191A5 (hr) | ||
| WO2023056029A1 (en) | Beta3-adrenergic agonists for treatment of disorders of hair growth | |
| BR112021003746B1 (pt) | Formulação para distribuição transdérmica de um ingrediente ativo a um mamífero, e kit | |
| Debruyne et al. | of Drugs in the Nail Apparatus |